|
1) Campana D, Coustan Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry (Clinical Cytometry). 1999; 38: 139-52
|
|
|
|
2) Campana D, Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol. 2004; 112: 8-15
|
|
|
|
|
|
3) Cave H, van der Werfften Bosch J, Suciu S, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med. 1998; 339: 591-8
|
|
|
|
|
|
4) van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet. 1998; 352: 1731-8
|
|
|
|
|
|
5) Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood. 2006; 108: 97-102
|
|
|
|
|
|
6) Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study; Children's Oncology Group. Blood. 2008; 111: 5477-85
|
|
|
|
|
|
7) Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL consortium protocol 95-01. Blood. 2007; 110: 1607-11
|
|
|
|
|
|
8) Van der Velden VH, Szczepanski T, Wijkhuijs JM, et al. Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia. 2003; 17: 1834-44
|
|
|
|
|
|
9) Van der Velden VH, Corral L, Valsecchi MG, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009; 23: 1073-9
|
|
|
|
|
|
10) Okamoto T, Yokota S, Katano N, et al. Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia—A retrospective study by the children's cancer and leukemia study group in Japan. Leukemia and Lymphoma. 2002; 43: 1001-6
|
|
|
|
|
|
11) 横田昇平, 岡本朋美, 鶴澤正仁. 急性白血 病における微小残存病変診断とその臨床応用. 日小血会誌. 2006; 20: 71-83
|
|
|
|
|
12) Hori T, Yamaji K, Yokota S, et al. Augmented therapy for MRD-positive patients with acute lymphoblastic leukemia can reduce the MRD levels and the risk of relapse: A report from the Japanese childhood cancer and leukemia study group ALL 2000 MRD pilot study. Blood. 2008; 112: 117 (abstr 301)
|
|
|
|
|
|
13) Ekert C, Biondi A, Seeger K, et al. Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukemia. Lancet. 2001; 358: 1239-41
|
|
|
|
|
|
14) Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia. 2002; 16: 1668-72
|
|
|
|
|
|
15) Sramkova L, Muzikova K, Fronkova E, et al. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007; 48: 93-100
|
|
|
|
|
|
16) Pongers-Willemse MJ, Seriu T, Stolz F, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunogloblin and T cell receptor gene rearrangements and TAL1 deletion as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia. 1999; 13: 110-8
|
|
|
|
|
|
17) van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and stadardization of PCR primers and protocols for detection of immunogloblin and T-cell receptor gene recombinants in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17: 2257-317
|
|
|
|
|
|
18) Flohr T, Schrauder A, Cazzaniga G, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunogloblin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia. 2008; 22: 771-82
|
|
|
|
|
|
19) Van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guideline for interpretation of real-time quantitative PCR data. Leukemia. 2007; 21: 604-11
|
|
|
|
|
|
20) Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood. 2005; 105: 821-6
|
|
|
|
|
|
21) Flotho C, Coustan-Smith E, Pei D, et al. Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood. 2006; 108: 1050-7
|
|
|
|
|
|
22) Flotho C, Coustan-Smith E, Pei D, et al. A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood. 2007; 110: 1271-7
|
|
|
|
|